UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixto

Annals of oncology, 2018-12, Vol.29 (12), p.2341-2347

2018

Volltextzugriff (PDF)

Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo

Annals of oncology, 2020-09, Vol.31 (9), p.1216-1222

2020

Volltextzugriff (PDF)

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab

Annals of oncology, 2016-08, Vol.27 (8), p.1519-1525

2016

Volltextzugriff (PDF)

Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial

Annals of oncology, 2021-12, Vol.32 (12), p.1590-1596

2021

Volltextzugriff (PDF)

Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy

Annals of oncology, 2015-01, Vol.26 (1), p.95-100

2015

Volltextzugriff (PDF)

Treatment and outcomes of patients in the Brain Metastases in Breast Cancer Network Registry

European journal of cancer (1990), 2018-10, Vol.102, p.1-9

2018

Volltextzugriff (PDF)

Diagnostik, Therapie und Nachsorge beim Mammakarzinom

Gynäkologe (Berlin), 2016-12, Vol.49 (12), p.949-959

2016

Volltextzugriff (PDF)

Vaginale und minimal-invasive Zugangswege in der Urogynäkologie – immer möglich?

Gynäkologe (Berlin), 2016-12, Vol.49 (12), p.915-920

2016

Volltextzugriff (PDF)

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab

Annals of oncology, 2019-07, Vol.30 (7), p.1180-1180

2019

Volltextzugriff (PDF)

Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study

Breast cancer research and treatment, 2019-06, Vol.175 (2), p.389-399

2019

Volltextzugriff (PDF)

Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapy

Annals of oncology, 2021-04, Vol.32 (4), p.500-511

2021

Volltextzugriff (PDF)

Influence of PIK3CA mutations on breast cancer proliferation, lymphocyte infiltration and clinical outcome: Pooled analysis of 484 patients from three prospective multicentre GBG trials

Annals of oncology, 2019-05, Vol.30, p.iii6-iii6

2019

Volltextzugriff (PDF)

Corrections to “PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab”

Annals of oncology, 2019-07, Vol.30 (7), p.1180-1180

2019

Volltextzugriff (PDF)

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab

Annals of oncology, 2018-10, Vol.29 (10), p.2151-2151

2018

Volltextzugriff (PDF)

Metastatic or locally advanced breast cancer patients: towards an expert consensus on nab-paclitaxel treatment in HER2-negative tumours—the MACBETH project

Cancer chemotherapy and pharmacology, 2019-02, Vol.83 (2), p.301-318

2019

Volltextzugriff (PDF)

Impact of nab-paclitaxel dose reduction on survival of the randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy of weekly nab-paclitaxel (nP) with solvent-based paclitaxel (P) followed by anthracycline/cyclophosphamide for patients with early breast cancer (BC)

Annals of oncology, 2018-10, Vol.29, p.viii60-viii60

2018

Volltextzugriff (PDF)

The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer

Current medical research and opinion, 2016-07, Vol.32 (7), p.1217-1224

2016

Volltextzugriff (PDF)

Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer

Breast cancer research and treatment, 2018-02, Vol.168 (1), p.179-187

2018

Volltextzugriff (PDF)

Validation of the MammaTyper® pathological complete response (pCR)-score as a predictor for response after neoadjuvant chemotherapy (NACT) in patients with early breast cancer (BC)

Annals of oncology, 2018-10, Vol.29, p.viii53-viii53

2018

Volltextzugriff (PDF)

Evaluation of the MammaTyper® as a molecular predictor for pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) and outcome in patients with different breast cancer (BC) subtypes

Annals of oncology, 2018-10, Vol.29, p.viii73-viii73

2018

Volltextzugriff (PDF)

BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial

Breast cancer research and treatment, 2017-12, Vol.166 (3), p.775-785

2017

Volltextzugriff (PDF)

Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab – a translational project in the neoadjuvant GeparQuinto trial

British journal of cancer, 2012-09, Vol.107 (6), p.956-960

2012

Volltextzugriff (PDF)

Bildgebende Diagnostik beim duktalen Carcinoma in situ der weiblichen Brust (DCIS)

Gynäkologe (Berlin), 2012-04, Vol.45 (4), p.263-268

2012

Volltextzugriff (PDF)

Prediction of ovulation by urinary hormone measurements with the home use ClearPlan® Fertility Monitor: comparison with transvaginal ultrasound scans and serum hormone measurements

Human reproduction (Oxford), 2000-12, Vol.15 (12), p.2478-2482

2000

Volltextzugriff (PDF)

Sentinel-Lymphknoten – Der positive Sentinel – mit und ohne Konsequenz?

Senologie (Stuttgart), 2011-10, Vol.7 (3), p.130-133

Schem, C.

2011

Volltextzugriff (PDF)

1 – 25 von 475

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(243)
Mit Volltextzugriff
(351)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixto

Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab

Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial

Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy

Treatment and outcomes of patients in the Brain Metastases in Breast Cancer Network Registry

Diagnostik, Therapie und Nachsorge beim Mammakarzinom

Vaginale und minimal-invasive Zugangswege in der Urogynäkologie – immer möglich?

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab

Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study

Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapy

Influence of PIK3CA mutations on breast cancer proliferation, lymphocyte infiltration and clinical outcome: Pooled analysis of 484 patients from three prospective multicentre GBG trials

Corrections to “PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab”

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab

Metastatic or locally advanced breast cancer patients: towards an expert consensus on nab-paclitaxel treatment in HER2-negative tumours—the MACBETH project

Impact of nab-paclitaxel dose reduction on survival of the randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy of weekly nab-paclitaxel (nP) with solvent-based paclitaxel (P) followed by anthracycline/cyclophosphamide for patients with early breast cancer (BC)

The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer

Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer

Validation of the MammaTyper® pathological complete response (pCR)-score as a predictor for response after neoadjuvant chemotherapy (NACT) in patients with early breast cancer (BC)

Evaluation of the MammaTyper® as a molecular predictor for pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) and outcome in patients with different breast cancer (BC) subtypes

BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial

Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab – a translational project in the neoadjuvant GeparQuinto trial

Bildgebende Diagnostik beim duktalen Carcinoma in situ der weiblichen Brust (DCIS)

Prediction of ovulation by urinary hormone measurements with the home use ClearPlan® Fertility Monitor: comparison with transvaginal ultrasound scans and serum hormone measurements

Sentinel-Lymphknoten – Der positive Sentinel – mit und ohne Konsequenz?

Suchergebnisse filtern